What does KPV do? Benefits and evidence
An alpha-MSH fragment studied for gut inflammation in animals, with no human dosing trial.
Also called: Lys-Pro-Val, Lysine-proline-valine, alpha-MSH(11-13), KPV acetate.
Anti-inflammatory and antimicrobial peptides · C-terminal alpha-MSH tripeptide with preclinical anti-inflammatory activity · Evidence: Animal studies only.
KPV is a three-amino-acid fragment of alpha-MSH. Gut-inflammation findings come from cells and animals, including mice given KPV by mouth. No published human dosing, benefit or safety study was found. People report oral and injected use, but neither has an established human dose. Product identity and long-term risks remain uncertain.
- In mouse studies, it reduced gut inflammation, including in mice given it by mouth. (animal)
- A few users report gut-symptom relief or less bloating; another reported no clear benefit. (Reported by users)
- In an animal study, it sped healing of wounds on the eye surface in rabbits. (animal)
Uses in the sources
- People report using it for gut symptoms and inflammation. The supporting colitis experiments are in mice, not human trials. (Reported by users) (source)
- Topical wound and skin uses are discussed, but FDA found no human effectiveness studies. Rabbit eye-wound results do not support home eye drops. (Reported by users) (source)
Related to KPV
- LL-37: A human defense peptide with mixed topical wound-trial results and no established injection regimen.
- BPC-157: An experimental repair peptide with mostly animal evidence and a few small human reports.
- GHK-Cu: A copper-binding skin peptide with small topical studies and untested systemic injections.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Concerns regarding the public health risks associated with unapproved peptide products, Therapeutic Goods Administration and Chief Medical Officer · Therapeutic Goods Administration · 2026
- Evaluation of KPV-related Bulk Drug Substances (KPV (free base) and KPV acetate) for Inclusion on the 503A Bulk Drug Substances List, FDA · 2026
- Federal Register: nonbinding draft HHS interim policy, October 30 2026, 2026
- HHS 503A peptide interim enforcement policy and conditions, October 30 2026, 2026
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026, FDA · FDA · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Ulcerative colitis, NHS · 2026
- Unapproved peptide product promoters and suppliers are put on notice, Therapeutic Goods Administration · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.